SUMMARY: The American Cancer Society estimates that for 2025, about 226,650 new cases of lung cancer will be diagnosed and 124,730 patients will die of the disease. Lung cancer is the leading cause of cancer-related mortality in the United States. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers and Adenocarcinoma is now the most frequent histologic subtype of lung cancer.
Stage III NSCLC represents a diverse and complex clinical scenario, historically guided by resectability and nodal involvement. Approximately one third of all patients with NSCLC have Stage III, locally advanced disease at the time of initial presentation and 60 to 90% of these patients have unresectable disease. However, recent ASCO guideline updates emphasize the integration of biomarker testing and precision medicine to improve outcomes across both resectable and unresectable disease.
Unresectable Stage III NSCLC with EGFR Mutation: Osimertinib Now Preferred
The Phase III LAURA trial established a new benchmark for patients with unresectable Stage III NSCLC harboring common EGFR mutations (exon 19 deletion or exon 21 L858R mutation). Osimertinib (TAGRISSO®), administered after completion of definitive chemoradiotherapy, led to a nearly 7-fold improvement in median Progression-Free Survival (39.1 vs 5.6 months; HR 0.16, P<0.001) compared with placebo. The incidence of brain metastases was also significantly reduced (8% vs 29%).
Given this magnitude of benefit and the modest toxicity profile (Grade ≥3 adverse events in 35%, including low rates of severe pneumonitis), Osimertinib is now considered the preferred consolidation therapy in this setting. Immune checkpoint inhibitors (ICIs), commonly used in other NSCLC populations, should be avoided in EGFR-mutated cases due to lack of efficacy and potential toxicity with sequential therapy.
Resected Stage III NSCLC: Targeted Adjuvant Therapies Lead the Way
EGFR-Mutated Disease – Adjuvant Osimertinib
Updated results from the Phase III ADAURA trial confirmed that adjuvant Osimertinib for 3 years significantly improves both Disease-Free Survival (DFS) and Overall Survival (OS) in patients with completely resected Stage IB–IIIA EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC. For patients with Stage IIIA, the DFS was extended to 55.1 months vs 14.4 months (HR=0.22), and 5-year OS rates reached 85% with Osimertinib compared to 67% with placebo (HR=0.37). There was greater DFS and OS benefit with adjuvant Osimertinib among patients with Stage III disease than that observed for Stage II or IB.
Platinum-based chemotherapy remains recommended before initiating Osimertinib, despite its non-mandatory use in ADAURA trial. Clinicians should counsel patients on the 3-year treatment duration plan with Osimertinib, cost considerations, and manageable toxicity profile.
ALK-Positive Disease – Adjuvant Alectinib
The Phase III ALINA trial established that 2 years of adjuvant Alectinib (ALECENSA®) as a superior alternative to chemotherapy in completely resected stage II–IIIA ALK-rearranged NSCLC. Two-year DFS was 93.8% with alectinib versus 63.0% with chemotherapy (HR=0.24; P<0.001). Alectinib also significantly reduced CNS relapse risk. While the trial did not include chemotherapy in the Alectinib arm, many experts still recommend preceding adjuvant Alectinib with four cycles of platinum–Pemetrexed doublet chemotherapy, based on known chemosensitivity in ALK-positive tumors.
Targeted Therapy for Rare Driver Mutations: Proceed with Caution
Although actionable mutations like ROS1 and RET are increasingly identified, there is limited evidence to guide adjuvant or consolidation therapy in Stage III NSCLC for these alterations. Clinicians should be cautious when extrapolating data from EGFR or ALK trials, given the lack of prospective data in this setting.
Immunotherapy in the Perioperative Setting: Expanding Options for Resectable Stage III NSCLC
Emerging data support the use of neoadjuvant and perioperative chemoimmunotherapy in resectable Stage III NSCLC without EGFR or ALK alterations. Trials such as CheckMate-816 (Nivolumab), KEYNOTE-671 (Pembrolizumab), AEGEAN (Durvalumab), and CheckMate-77T showed improvements in pathological Complete Response and Event-Free Survival when Immune Checkpoint Inhibitors (ICIs) were added to neoadjuvant chemotherapy.
These studies typically continued ICI therapy for up to one year post-surgery. Although overall survival data remain immature, perioperative immunotherapy has become a viable treatment paradigm in patients with PD-L1-positive, driver mutation-negative disease. Conversely, patients with EGFR or ALK alterations should not be offered ICIs in the adjuvant or consolidation setting.
Take-Home Message
ASCO’s guideline update underscores a paradigm shift in Stage III NSCLC, integrating molecular profiling and personalized treatment strategies. Key recommendations include:
- Osimertinib for unresectable EGFR-mutant NSCLC post-chemoradiotherapy
- Adjuvant Osimertinib or Alectinib in resected Stage III disease with EGFR or ALK alterations, respectively
- Chemoimmunotherapy in resectable, driver mutation-negative Stage III NSCLC
As the treatment landscape rapidly evolves, multidisciplinary collaboration and upfront biomarker testing are essential to optimize outcomes.
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. Singh N, Früh M, Gubens MA, et al. JCO Oncol Pract. 2024;21:463-466
